Replies to post #16700 on Momenta Pharmaceuticals, Inc. (MNTA)

[Boing x 2]

DewDiligence,

Thank you for your feedback. It is appreciated very much.

Boin x 2

[alternatepatel]

M923 deal before FDA approval makes no sense. Difficult to assign value without knowing interchangeability status.

Other factor that may influence an early deal is cash depletion caused by long delay in glatopa 40mg approval.

There will be enough of interest in this asset & so MNTA will be in no hurry.